What CareFirst v. Amgen Teaches—and What It Still Does Not Decide

CareFirst v. Amgen offers a direct answer to the question at the center of this series: patent ownership and the end of an HSR waiting period do not, by themselves, answer whether a transaction was exclusionary. The FTC’s position is that the relevant inquiry follows the competitive function of the Amgen–Roche restructuring, including Amgen’s exclusive control over two pending applications, rather than stopping at the formal labels “license,” “patent,” or “early termination.” The durable judgment is therefore layered: identify what was acquired, what that control could change, which later acts may be protected, and what the record still cannot establish.

Why formal completion does not end the antitrust question

Start with the asset as it existed when Amgen and Roche restructured their relationship in 2004. It was not only a permission to sell Enbrel. The FTC describes a transfer of exclusive rights in the relevant etanercept patent family, control over prosecution of two pending Roche applications, and the ability to sue companies seeking to market etanercept biosimilars. Amgen already had a non-exclusive license that, in the FTC’s account, allowed it to sell Enbrel without infringing Roche’s rights. Roche had retained the ability to commercialize a version or license the rights to a potential competitor. The alleged change was the removal of that non-exclusive, open-ended arrangement and the creation of an exclusive position under Amgen’s control.

That distinction explains why ownership is not a complete answer. Ownership or exclusive control can be competitively important because it determines who can decide whether a potential route to technology remains available. In this case, the pending applications also carried four connected capabilities. Amgen could control prosecution and choose which supported claims to pursue. It inherited Roche’s earlier priority position, according to the FTC’s explanation. It could use continuation practice to pursue related claims from a parent application while the relevant conditions allowed. And it held a position whose unsettled scope could make rival planning more difficult. None of those capabilities guaranteed a patent or proved an unlawful purpose. Together, they explain why the acquisition could be analyzed before issuance.

The chronology then gives the capabilities a possible competitive consequence. Immunex launched Enbrel in 1998, and Amgen later acquired Immunex after Enbrel became a blockbuster. The key patents were expected to expire in 2012. The FTC says the applications acquired through the 2004 restructuring produced patents in 2011 and 2012, giving Amgen exclusive rights covering Enbrel through April 24, 2029. Amgen then obtained permanent injunctions against Sandoz and Bioepis that reportedly lasted until that date. The later patents and injunctions are not proof by themselves that the 2004 transaction violated Section 2. They are later links in the sequence that the acquisition-based theory asks a court to interpret.

Section 2 supplies the right level of abstraction. The FTC describes monopolization as requiring willful acquisition or maintenance of monopoly power through exclusionary conduct rather than through a superior product, business acumen, or historic accident. Exclusionary conduct tends to impair rivals’ opportunities and does not further competition on the merits, or does so in an unnecessarily restrictive way. That standard does not make patent ownership suspicious as such. It asks whether a particular acquisition, in a particular market position, helped preserve power through something other than competing on the merits.

The end of the HSR waiting period answers a different question. The 2004 restructuring was submitted under the Hart-Scott-Rodino Act, and the FTC granted early termination of the waiting period. Under the meaning set out in the FTC’s brief, early termination records that neither the FTC nor DOJ intended to take action during that waiting period. It is not a determination of legality, an endorsement of the transaction, or a bar to later antitrust scrutiny. It does not certify the future use of the acquired rights, assess every later patent claim, or decide whether the deal maintained monopoly power through exclusionary conduct.